2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
04:30 p.m. - 06:00 p.m.
MCCNO - 260-262
Technology and Procedures, Molecular Testing, Omics Technologies, Bioinformatics, Computational Biology, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Immunotherapy, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Study Population, Animal Model
PAPER

658 Impact of PTPN1/PTPN2 inhibition on the efficacy of CAR T cells and bispecific antibodies in lymphoma

Yue Qin, PhD, Nicholas Zolnerowich2, Sidney Wang3, Joanna K Chorazeczewski, MS4, Lei Gao, PhD5, Xiufen Chen, PhD6, Justin Kline7, James Godfrey, MD8
1 City of Hope, Duarte, California, United States
2 University of Chicago, Chicago, United States
3 University of Chicago, Chicago, United States
4 University of Chicago, Chicago, United States
5 City of Hope, Duarte, California, United States
6 University of Chicago, Chicago, United States
7 University of Chicago, Chicago, United States
8 City of Hope, Duarte, California, United States

Introduction: Bispecific antibodies (BsAb) and chimeric antigen receptor (CAR) T cells have transformed the treatment of diffuse large B-cell lymphoma (DLBCL). Despite this, most patients will relapse after BsAb and CAR T cell treatment, which underscores the need to identify novel treatments to improve the curative-potential of these immunotherapies. The PTPN1 and PTPN2 protein phosphatases negatively regulate cytokine and T cell receptor signaling, and function as important immune checkpoints. AC484 is a first-in-class, orally bioavailable PTPN1/PTPN2 inhibitor that stimulates robust anti-tumor immunity, significantly improves responses to checkpoint blockade therapy in murine solid tumor models (Baumgartner, Nature, 2023), and is currently being investigated in a phase I study for advanced solid tumors alone and in combination with PD-1 blockade. AC484 promotes anti-tumor immune responses by sensitizing tumor cells to IFNγ, inflaming the tumor microenvironment, and improving the activation and function of various immune cells. Based on these observations, we hypothesized AC484 would significantly enhance the pre-clinical anti-lymphoma activity of BsAbs and CAR T cells.

Methods: The effect of AC484 (0.1-10uM) on CAR-T and BsAb-exposed T cells was assessed in co-cultures with murine (A20, tFL-P6) and human (OCI-Ly8, OCI-Ly1, HT, CTB1) lymphoma cells. In vivo synergy between AC484 and CAR-T or BsAb was evaluated using human lymphoma xenografts (OCI-Ly8) and syngeneic models (tFL-P6), where AC484 was administered by oral gavage for 7 days (20 mg/kg/d) to mice with established lymphomas.

Results: Short-term incubation of AC484 with human second generation CD19-directed CAR T cells significantly increased CAR and cytokine signaling following stimulation with CD19 tetramers and IL7/IL-15, as reflected by increased ZAP70, ERK, AKT, NF-kB (p65), and phospho-STAT5 levels. When added to co-cultures of CAR T cells and OCI-Ly8 DLBCL cells for 48 hours, AC484 significantly increased T cell activation (CD25, CD69, ICOS), production of effector cytokines (IFNγ and TNFα), and lymphoma cell lysis. Human CAR T cells exposed to AC484 during the CAR manufacturing process modestly improved the survival of NSG mice xenografted with OCI-Ly8 lymphomas compared to CAR T cells manufactured in standard control conditions. However, AC484 administration to NSG mice after CAR T cell transfer markedly prolonged the survival of mice bearing OCI-Ly8 xenografts compared to vehicle control. 

Similar to our findings with CAR T cells, AC484 led to a significant and dose-dependent increase in T cell activation (CD25 and CD69 upregulation) when healthy human donor T cells were cultured with DLBCL cells (OCI-Ly1, HT, CTB1), and the CD20xCD3 BsAb, epcoritamab. BsAb-induced tumor cell lysis was also strikingly increased by AC484, even at low effector:target cell ratios. Analogous results were observed with murine A20 and tFL-P6 lymphoma cells exposed to syngeneic CD3+ T cells and a murine CD20xCD3 BsAb. AC484 treatment in combination with CD20xCD3 BsAb led to complete eradication of disseminated intravenously-engrafted tFL-P6 lymphomas and significantly improved survival of syngeneic C57BL/6 mice compared to treatment with vehicle, AC484, or BsAb alone.

Lastly, as we and others have demonstrated the importance of FAS/FASL interactions in mediating T cell lysis of both target-antigen positive and target antigen-negative bystander cells by CAR T cells and BsAb, we sought to evaluate the impact of AC484 on FAS expression and bystander killing. Incubation of murine and human lymphoma cells with increasing doses of AC484 and IFNγ (10ng/mL) led to significant and dose-dependent increases in FAS tumor cell expression. Moreover, when syngeneic murine T cells were cultured with a CD20xCD3 BsAb and a mixed 1:1 ratio of CD20+ and CD20- tFL-P6 lymphoma cells, AC484 increased BsAb-mediated lysis of CD20+ lymphoma cells as expected, but also led to a striking increase in bystander killing of CD20- tumor cells compared to vehicle control.

Conclusion: These findings position the PTPN1/2 inhibitor, AC484, as a rational partner worthy of future clinical evaluation in combination with BsAb and CAR T cells in lymphoma, as AC484 not only increases the clearance of CD19+/CD20+ target cells by BsAb and CAR T cells, but may also mitigate target antigen-negative relapse – one of the major mechanisms driving resistance to BsAb and CAR T cells in the clinic.

Nicholas Zolnerowich: No relevant conflicts of interest to declare.